August 28, 2008 (FinancialWire) Shares of Cell Genesys Inc. (NASDAQ: CEGE) plunged to an all-time low after the company halted a clinical trial of its prostate cancer vaccine GVAX because of patient deaths. Shares of Dendreon Corp. (NASDAQ: DNDN), which is developing its own prostate cancer vaccine called Provenge, also declined. The company stopped VITAL-2, one of two late-stage tests of GVAX, because patients who received GVAX were dying more often than those who received only a standard treatment. The company's stock plunged $2.02, or 72 percent, to 79 cents per share, and fell as far as 69 cents per share, less than half its previous all-time low of $1.55, which was set in January. GVAX is the company's lead product candidate and earlier clinical trials, as well as the ongoing VITAL-1 tests, include patients who are healthier than those in VITAL-2, and in those studies. GVAX uses whole cells and targets many proteins within tumors, while Provenge targets only a single protein. FinancialWire is a fully independent, proprietary news wire service of Investrend Information (a division of Investrend Communications, Inc.). FinancialWire news is written by professional journalists, dedicated to pure journalistic standards. FinancialWire does not receive or accept any compensation from any individual or subject company (or representative thereof) for its news or opinions. All FinancialWire news is available at http://www.financialwire.net . Please address any inquiries to feedback@financialwire.net . Free annual reports for companies mentioned in the news are available at http://investrend.ar.wilink.com/?level=279 .

(Distributed for Investrend Communications, Inc. via M2 Communications Ltd (www.m2.com)) .END